The international Union Against Tuberculosis and Lung Diseases, Paris Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2009
NCT00640887
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

International Union Against Tuberculosis and Lung Diseases | The international Union Against Tuberculosis and Lung Diseases (IUATLD), Paris, France

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 2)

Communicable Diseases (Phase 2)

HIV Infections (Phase 2)

Infections (Phase 2)

Tuberculosis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 8